Research progress in the role of STMN1 in tumor.
10.11817/j.issn.1672-7347.2025.240660
- Author:
Xingxing MA
1
,
2
;
Muzi LI
3
;
La CHEN
3
;
Huijuan MEI
3
;
Ziye RONG
4
Author Information
1. First School of Clinical Medicine, Anhui Medical University, Hefei
2. 2412852241@qq.com.
3. Department of Immunology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
4. Department of Immunology, School of Basic Medicine, Anhui Medical University, Hefei 230032, China. 2021500003@ahmu.edu.cn.
- Publication Type:English Abstract
- Keywords:
ferroptosis;
microtubule;
stathmin 1;
tumor;
tumor drug resistance;
tumor immunity
- MeSH:
Humans;
Stathmin/metabolism*;
Neoplasms/genetics*;
Biomarkers, Tumor/metabolism*;
NF-kappa B/metabolism*;
Cell Proliferation;
Drug Resistance, Neoplasm
- From:
Journal of Central South University(Medical Sciences)
2025;50(6):1052-1059
- CountryChina
- Language:Chinese
-
Abstract:
Stathmin 1 (STMN1) is a microtubule-binding cytoplasmic phosphoprotein that promotes microtubule depolymerization or inhibits microtubule assembly, thereby regulating cytoskeletal organization and cell cycle progression. STMN1 is upregulated in a variety of malignant tumors, where it drives proliferation, invasion, metastasis, and angiogenesis through classic pathways such as nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and ferroptosis. STMN1 can also modulate the function of immune cells, thereby influencing antitumor immunity. Clinical data show that its high expression correlates positively with tumor drug resistance and poor prognosis, suggesting that STMN1 has potential as a tumor biomarker and therapeutic molecular target with important clinical significance.
